ProKidney Corp. Class A (PROK)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$1.65−$0.0300 (−1.79%) on the dayAs of the close; data may be delayed.
PROK price, last 12 months
Key stats
- Previous close
- $1.68
- Open
- $1.67
- Day range
- $1.57 – $1.69
- 52-week range
- $1.30 – $3.48
- Volume
- 2.1M
- Avg volume (20 days)
- 1.7M
- Market cap
- $334.3M
Performance
1W−13.6%
1M−5.2%
3M−9.8%
6M−6.8%
YTD−26.3%
1Y−39.3%
vs S&P 500, 1Y−56.1 pts
Technicals and fundamentals
About ProKidney Corp. Class A
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $334.3M